trial · primary record
Pozelimab + Cemdisiran
Generalized Myasthenia Gravis
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 288 |
| Primary completion | 2028-11-11 |
| Primary endpoint | Change in Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score |
| Registry ID | NCT05070858 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:39:33.409Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05070858
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.